Clinical trials: PE - Pulmonary Thromboembolism
This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.
Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism
Purpose and rationale: Acute pulmonary embolism (PE) is a common and often fatal disease, with an approximately 30% mortality rate without treatment. Treatment is important to reduce mortality and recurrence in acute PE.
- Trial name
- NCT01956955
- Testing
- enoxaparin ,alteplase, unfractionated heparin
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Ataturk University
Pulmonary Embolism, Deep Vein Thrombosis
Discharge ALERT: Quality Improvement Initiative
Brigham and Women's Hospital will coordinate a Quality Improvement Initiative at other hospitals that focuses on whether physician notification prior to discharge of high risk VTE patients will reduce the incidence of VTE after…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Prophylaxis, Venous Thromboembolism
- Trial name
- Discharge (NCT00853463)
- Testing
- Alert
- Where
- 22 sites in United States
- Volunteers
- 2,515 people
- Sponsor
- Brigham and Women's Hospital
Acute Pulmonary Embolism, Thromboembolism
SYMPHONY-PE Study for Treatment of Pulmonary Embolism
Evaluation of the Safety and Efficacy of the Symphony Thrombectomy System in the Treatment of Pulmonary Embolism
- Conditions
- Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis
- Trial name
- NCT06062329
- Testing
- Symphony Thrombectomy System
- Where
- 19 sites in United States
- Volunteers
- 110 people
- Sponsor
- Imperative Care, Inc.
Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).
- Conditions
- Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension, Right Ventricular Dysfunction, Pulmonary Embolism (PE)
- Trial name
- PERSEUS (NCT07855679)
- Testing
- Routine clinical care (no study intervention)
- Where
- 16 sites in Italy, Poland and 1 more
- Volunteers
- 5,000 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Pulmonary Thromboembolism
Thromboembolic Events in Severe COVID-19 Patients
The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19.
- Trial name
- COVICLOT (NCT04405869)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19 Pneumonia, Pulmonary Embolism
External Validation of the CHOD Risk Scale
Severe COVID-19 is associated with a hypercoagulable state, with a high risk of thrombotic phenomena such as pulmonary thromboembolism (PE).
- Trial name
- CHOD-1 (NCT04889261)
- Where
- Spain
- Volunteers
- 245 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Pulmonary Embolism, Venous Thromboembolism
Residual Pulmonary Vascular Obstruction Index Computed With Ventilation/Perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT)
Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk.
- Trial name
- PRONOSPECT (NCT06372730)
- Testing
- Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT)
- Where
- 13 sites in France
- Volunteers
- 665 people
- Sponsor
- University Hospital, Brest
Renal Insufficiency
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic…
- Trial name
- VERDICT (NCT02664155)
- Testing
- Apixaban, Rivaroxaban, Heparin
- Where
- 31 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Venous Thromboembolism, Thoracic Surgery
Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection
The purpose of this study is to determine the incidence of post-operative venous thromboembolism (VTE) in patients undergoing major esophageal resection for malignancy.
- Conditions
- Venous Thromboembolism, Thoracic Surgery, Esophageal Cancer
- Trial name
- NCT03115541
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 187 people
- Sponsor
- McMaster University
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
FlowTriever All-Comer Registry for Patient Safety and Hemodynamics
To evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE).
- Trial name
- FLASH (NCT03761173)
- Testing
- FlowTriever System, Anticoagulation Agents
- Where
- 81 sites in United States, Austria and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Inari Medical
Pulmonary Embolism, Deep Vein Thrombosis
Multi-Center Human Alert Trial to Prevent DVT and PE
To evaluate physician response to human alerts that inform the clinician that his/her patient may be eligible for thromboprophylaxis.
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
- Trial name
- NCT00409136
- Testing
- Human Alert
- Where
- 26 sites in United States
- Volunteers
- 2,496 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Embolism, Pulmonary Thromboembolism
Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
Recombinant streptokinase (r-SK) is an effective thrombolytic agent developed with gene engineering. Its characteristics of high output and low production cost make it affordable in treating acute myocardial infarction (AMI) in…
- Trial name
- RESUPEC (NCT00968929)
- Testing
- Recombinant Streptokinase, Urokinase
- Where
- 8 sites in China
- Volunteers
- 83 people
- Sponsor
- Beijing Chao Yang Hospital
Thrombosis, Deep Venous Thrombosis
Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer
Cancer is a well known risk factor for venous thromboembolism (VTE) such as deep venous thrombosis (DVT) and pulmonary embolism (PE).
- Conditions
- Thrombosis, Deep Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- GIVTE (NCT00660205)
- Where
- Denmark
- Volunteers
- 285 people
- Sponsor
- University of Aarhus